Expertise in
1
conditions

Dr. Gary E. Goodman

Pediatrics
CHOC Children's At Mission Hospital
27700 Medical Center Rd, 
Mission Viejo, CA 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Referral may be required
Before you request
Expertise in
1
conditions
CHOC Children's At Mission Hospital
27700 Medical Center Rd, 
Mission Viejo, CA 

Overview

Gary Goodman is a Pediatrics provider practicing medicine in Mission Viejo, California.

Dr. Goodman is highly rated in 1 condition, according to our data. His clinical expertise encompasses Asthma in Children, Lissencephaly 1, Bilateral Perisylvian Polymicrogyria, and Agyria Pachygyria Polymicrogyria.

He is actively involved in clinical research, co-authoring 95 peer reviewed articles and participating in 53 clinical trials. Dr. Goodman is currently accepting new patients.

Specialties

Pediatrics

Licenses

Pediatric Critical Care Medicine in CA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 3 Less Insurance Carriers -

Locations

CHOC Children's at Mission Hospital
27700 Medical Center Rd, Mission Viejo, CA 92691
Other Locations
CHOC Children's Hospital
1201 W La Veta Ave, Orange, CA 92868

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

53 Clinical Trials

Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
Enrollment Status: Recruiting
Publish Date: September 04, 2026
Intervention Type: Procedure, Biological, Drug, Other
Study Drugs: Obinutuzumab, Venetoclax
Study Phase: Phase 3
Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Enrollment Status: Recruiting
Publish Date: August 20, 2026
Intervention Type: Drug, Biological
Study Drugs: Fluorouracil, Irinotecan, Irinotecan hydrochloride, Leucovorin, Leucovorin calcium, Paclitaxel, Ramucirumab
Study Phase: Phase 2
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Trametinib
Study Phase: Phase 2
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
View 8 Less Clinical Trials

95 Total Publications

Genes associated with genetic and rare lung diseases and the risk of lung cancer.
Genes associated with genetic and rare lung diseases and the risk of lung cancer.
Journal: Research square
Published: August 20, 2025
Similar Doctors
Expertise in
40
conditions
Dr. Shireen V. Guide
Pediatrics | Dermatology
Expertise in
40
conditions
Dr. Shireen V. Guide
Pediatrics | Dermatology
Referral may be required
Before you request
Rancho Santa Margarita, CA 
 (5.1 miles away)
949-858-3376
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Shireen Guide is a Pediatrics specialist and a Dermatologist practicing medicine in Rancho Santa Margarita, California. Dr. Guide is highly rated in 40 conditions, according to our data. Her clinical expertise encompasses Dystrophic Epidermolysis Bullosa, Erythroderma, Epidermolysis Bullosa Simplex, and Dominant Dystrophic Epidermolysis Bullosa. Dr. Guide is currently accepting new patients.

Expertise in
31
conditions
Dr. Ying H. Peng
Pediatrics | Neurology
Expertise in
31
conditions
Dr. Ying H. Peng
Pediatrics | Neurology
Referral may be required
Before you request
333 Corporate Drive, Suite 110, 
Ladera Ranch, CA 
 (2.1 miles away)
949-215-6662
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ying Peng is a Pediatrics specialist and a Neurologist practicing medicine in Ladera Ranch, California. Dr. Peng is highly rated in 31 conditions, according to our data. Her clinical expertise encompasses Memory Loss, Seizures, Generalized Tonic-Clonic Seizure, Thrombectomy, and Aortic Valve Replacement. Dr. Peng is board certified in American Board Of Psychiatry And Neurology. Dr. Peng is currently accepting new patients.

Expertise in
2
conditions
Expertise in
2
conditions
Referral may be required

UCI Health

101 The City Dr S, 
Orange, CA 
 (20.3 miles away)
714-456-8978
Languages Spoken:
English

Tallie Baram is a Pediatrics provider practicing medicine in Orange, California. Dr. Baram is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Genetic Epilepsy with Febrile Seizures Plus (GEFS+) and Epilepsy in Children.

Frequently Asked Questions about Dr. Gary E. Goodman

How do I make an appointment with Dr. Gary E. Goodman?

You can book an appointment with Dr. Gary E. Goodman by calling their office at 949-364-1400. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Gary E. Goodman a top-rated expert for Asthma in Children?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Gary E. Goodman is classified as an Advanced expert for Asthma in Children, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Gary E. Goodman specialize in?

While Dr. Gary E. Goodman is a Pediatrics, they have specific expertise in Asthma in Children, Lissencephaly 1, and Bilateral Perisylvian Polymicrogyria. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatrics.

Does Dr. Gary E. Goodman participate in research or clinical trials?

Yes. Dr. Gary E. Goodman has published 95 articles and abstracts on conditions like Asthma in Children. You can view a list of Dr. Gary E. Goodman's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Gary E. Goodman accept my insurance?

Dr. Gary E. Goodman accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 949-364-1400 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Goodman's expertise for a condition
ConditionClose
      View All 17 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile